School of Nursing, The University of Texas at Austin , Austin, TX, USA.
Neurol Res. 2020 Jul;42(7):537-546. doi: 10.1080/01616412.2020.1754640. Epub 2020 Apr 22.
An investigation of the prevalence of medication persistence and associated factors in order to inform effective strategies for improving medication persistence.
A systematic review of the literature from 2010 to the present was performed, using the PRISMA protocol. Primary and empirical observational studies of adult ischemic stroke or transient ischemic attack patients were included. PubMed, CINAHL, Web of Science, Cochrane Library, and PsycInfo databases were searched using the key terms , and .
Of four hundred twenty-eight journal articles retrieved, a final 18 articles were included. Short-term medication persistence was 46.2-96.7%, and long-term medication persistence was 41.7-93.0%. Identified hospital-related factors for medication persistence were stroke unit care, in-hospital medical complications, and early follow-up visit. Demographic factors for medication persistence were older age, and high/adequate financial status; disease-related factors were disease history, stroke subtype, and symptom severity. Age less than 75, female sex, comorbidity, antiplatelet medication switch, and polypharmacy were identified as factors of medication nonpersistence.
Stroke patients' medication persistence decreases over time, and persistence on antiplatelets, anticoagulants, and statin was poor. Several factors were associated with medication persistence, and these factors should be considered in future secondary preventative strategies.
调查药物坚持治疗的流行率和相关因素,为制定提高药物坚持治疗的有效策略提供信息。
采用 PRISMA 方案,对 2010 年至今的文献进行系统回顾。纳入了成年缺血性卒中和短暂性脑缺血发作患者的原始和经验性观察性研究。使用关键词 和 在 PubMed、CINAHL、Web of Science、Cochrane Library 和 PsycInfo 数据库中进行检索。
从 428 篇期刊文章中,最终纳入了 18 篇文章。短期药物坚持治疗率为 46.2%-96.7%,长期药物坚持治疗率为 41.7%-93.0%。与药物坚持治疗相关的医院相关因素有卒中单元护理、住院期间的医疗并发症和早期随访。与药物坚持治疗相关的人口统计学因素为年龄较大和高/足够的经济状况;与疾病相关的因素为病史、卒中亚型和症状严重程度。年龄小于 75 岁、女性、合并症、抗血小板药物转换和多种药物治疗被确定为药物不坚持治疗的因素。
随着时间的推移,卒中患者的药物坚持治疗率下降,抗血小板、抗凝和他汀类药物的坚持治疗率较差。一些因素与药物坚持治疗有关,这些因素应在未来的二级预防策略中加以考虑。